Abstract
Hypomethylating drugs are useful in the management of Myelodysplastic syndromes, but there are only few reports on chronic myelomonocycitic (CMML) leukemia patients. We describe our experience in 3 CMML patients treated with azacitidine. Two patients obtained partial response after 4 treatment cycles with only minor toxicity and are in continuous partial response, with stable peripheral blood counts, at 29 and 30 cycles from treatment start.
Lingua originale | English |
---|---|
pagine (da-a) | e2011011-e2011011 |
Rivista | Mediterranean Journal of Hematology and Infectious Diseases |
Volume | 3 |
DOI | |
Stato di pubblicazione | Pubblicato - 2011 |
Keywords
- 5-azacytidine
- CMML